Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep621 | Pituitary and Neuroendocrinology | ECE2020

9-CIS retinoic acid decreases pomc expression and cell viability in experimental model of ectopic cushing syndrome

Regazzo Daniela , Barbot Mattia , Ceccato Filippo , Nora Albiger , laura lizzul , Fiorella Calabrese , Federico Rea , Andrea Zuin , Boscaro Marco , Occhi Gianluca , Carla Scaroni

Ectopic Cushing syndrome (EAS) is a rare condition characterized by ACTH-dependent hypercortisolism resistant to normal physiologic suppression by glucocorticoids. EAS is due to an extra-pituitary tumor producing bioactive molecules generated by post-translational cleavage of the proopiomelanocortin gene (POMC). EAS is associated with significant morbidity and mortality and although surgical resection of the primary ACTH-producing tumor remains the mainstay of therapy, not all...

ea0032p519 | Endocrine tumours and neoplasia | ECE2013

mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids

Gagliano Teresa , Bellio Mariaenrica , Gentilin Erica , Mole Daniela , Tagliati Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Calabrese Fiorella , Ambrosio Maria Rosaria , Rea Federico , Uberti Ettore degli , Zatelli Maria Chiara

Background: Bronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphan of medical treatment. Human BC primary cultures may display resistance to everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), in terms of cell viability reduction.Aim: To assess whether the novel dual PI3K/mTOR inhibitor, NVP-BEZ235, may be effective in everolimus-resistant human BC tissues and cell lines. In addition, we search for possible mark...